CINV Existing And Pipeline Drugs Market Size By Product (Aloxi (Palonosetron), Zofran (Ondansetron)), By End-User (Hospitals, Specialty Clinics)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global CINV Existing and Pipeline Drugs market size was estimated at USD 1.85 billion in 2021 and is expected to surpass around USD 4.11 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 6.10% during the forecast period 2022 to 2030.

Overview of Global CINV Existing and Pipeline Drugs Market

Chemotherapy-induced nausea and vomiting (CINV) refers to nausea and vomiting associated with cancer chemotherapy. CINV is one of the most common side effects experienced by cancer patients undergoing chemotherapy. Presently, several drugs are available to manage CINV; however, side effects continue to be a key concern for patients and oncologists associated with chemotherapy. Companies such as Helsinn Holding S.A., Heron Therapeutics, Inc., and Tesaro, Inc. are striving to develop new and more efficacious therapeutic solutions to treat CINV.

 Report Scope of the CINV Existing and Pipeline Drugs Market

Increase in Incidence Rate of Various Types of Cancer

The world is witnessing a continuous increase in the incidence rate of various types of cancer, which results in rise in the number of patients undergoing chemotherapy. According to estimates from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries, and ranks third or fourth in a further 23 countries. These facts indicate that increase in cases of various types of cancer is likely to induce oncologists to prescribe chemotherapy to their patients for the effective treatment of cancer, thereby driving the CINV existing and pipeline drugs market.

Generally, 26% to 30% patients with cancer receive chemotherapy as a treatment option, and 70% to 80% of these patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms.

Companies Undertaking R&D Activities to Develop Advanced Drugs

Significant rise in cancer research and development efforts and increase in attention on the development of novel therapies are expected to drive the global CINV existing and pipeline drugs market over the next few years. Additionally, the introduction of new pharmaceuticals and the rapid growth of the healthcare industry are expected to propel the market in the near future. However, consumers' lack of information regarding the availability of innovative and effective pharmaceuticals and treatments is projected to impact the growth of the market in the next years.

SUSTOL (APF-530) Segment to Dominate Global Market

SUSTOL (APF-530) was launched in 2015. The approval of SUSTOL drugs is likely to drive the global market during the forecast period. Increase in the number of patients undergoing chemotherapy is expected to contribute to the growth of the global CINV existing and pipeline drugs market. Various sources indicate that 70% to 80% cancer patients on chemotherapy exhibit nausea and vomiting as major side effects.

Rolapitant to Witness Demand Due to Ability to Suppress Vomiting

Rolapitant was approved in 2015. Since then, the demand for the drug has increased among various countries. Pipeline drugs have shown better efficacy than existing drugs during the clinical study. Rolapitant is used with other drugs to delay nausea and vomiting caused by cancer drug treatment (chemotherapy). It acts by suppressing one of the body's natural chemicals (substance P/neurokinin 1) that produces vomiting. Therefore, the launch of these more efficacious drugs is likely to encourage physicians to prescribe these new drugs over existing drugs

Regional Outlook of Global CINV Existing and Pipeline Drugs Market

The global CINV existing and pipeline drugs market has been segmented into North America, Europe, Asia Pacific Latin America, and Middle East & Africa. North America was the largest market for CINV drugs in 2021, accounting for over 45% share. The region is expected to retain its leadership position during the forecast period. The market in North America is likely to expand at a CAGR of over 7% from 2022 to 2031.

Europe was the second largest market for CINV drugs in 2021. The launch of CINV pipeline drugs in Europe is projected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend.

The CINV existing and pipeline drugs market in Asia Pacific is driven by increase in penetration of western companies and rise in the number of cancer patients. Generic manufacturers in countries in Asia Pacific and emerging regions compete with the branded CINV drug manufacturers. The demand for generic versions of expired branded drugs is high in the region due to low purchasing power of the people. Strong economic growth in countries such as India and China and improving healthcare infrastructure are anticipated to drive the CINV existing and pipeline drugs market in Asia Pacific.

Analysis of Key Players in Global CINV Existing and Pipeline Drugs Market

Key players operating in the global CINV existing and pipeline drugs market include GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc. Each of these players has been profiled in the global CINV existing and pipeline drugs market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Key Developments in Global CINV Existing and Pipeline Drugs Market

• In October 2020, Tetra Bio-Pharma has unveiled its commercial vision on a Robust chemotherapy induced nausea & vomiting portfolio. Company has the strategy to bring the innovative therapies to patients suffering from chemotherapy-induced nausea & vomiting.
• In July 2019, Nuformix, the pharmaceutical development company used cocrystal technology and commenced the clinical studies for NXP001
• In July 2018, Glenmark Pharmaceuticals, one of the global leading companies in the pharmaceuticals, launched drug Akynzeo for chemotherapy-induced nausea in India and Nepal. Akynzeo is the combination of netupitant and palonosetron.

Some of the prominent players in the CINV Existing and Pipeline Drugs Market include:

GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., Tesaro, Inc., Baxter Healthcare, Barr Laboratories, Inc., Sun Pharma, and Sandoz (Novartis AG).

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global CINV Existing and Pipeline Drugs market

CINV Existing And Pipeline Drugs Market, By Product

• Aloxi (Palonosetron)
• Zofran (Ondansetron)
• Kytril (Granisetron)
• Emend (Aprepitant)
• Akynzeo (Netupitant-Palonosetron)
• Sustol
• Rolapitant

CINV Existing And Pipeline Drugs Market, By End-User

• Hospitals
• Specialty Clinics
• Diagnostic Centers

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global CINV Existing and Pipeline Drugs industry analysis from 2022 to 2030 to identify the prevailing CINV Existing and Pipeline Drugs industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global CINV Existing and Pipeline Drugs industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global CINV Existing and Pipeline Drugs industry trends, key players, market segments, application areas, and market growth strategies.